Characterization of serum cytokine profile in predominantly colonic inflammatory bowel disease to delineate ulcerative and Crohn's colitides
OY Korolkova, JN Myers, ST Pellom… - Clinical Medicine …, 2015 - journals.sagepub.com
Background As accessible diagnostic approaches fail to differentiate between ulcerative
colitis (UC) and Crohn's colitis (CC) in one-third of patients with predominantly colonic …
colitis (UC) and Crohn's colitis (CC) in one-third of patients with predominantly colonic …
[HTML][HTML] Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
CS Rumfield, ST Pellom, YM Morillon II… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background While prophylactic human papillomavirus (HPV) vaccines will certainly reduce
the incidence of HPV-associated cancers, these malignancies remain a major health issue …
the incidence of HPV-associated cancers, these malignancies remain a major health issue …
The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex
C Jochems, SR Tritsch, KM Knudson… - …, 2019 - Taylor & Francis
Here we describe a novel bifunctional fusion protein, designated N-809. This molecule
comprises the IL-15/IL15Rα superagonist complex containing the Fc-domain of IgG1 (N-803 …
comprises the IL-15/IL15Rα superagonist complex containing the Fc-domain of IgG1 (N-803 …
[HTML][HTML] The Use of a Humanized NSG-β2m−/− Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp …
YM Morillon, C Smalley Rumfield, ST Pellom… - Frontiers in …, 2020 - frontiersin.org
The lack of serial biopsies in patients with a range of carcinomas has been one obstacle in
our understanding of the mechanism of action of immuno-oncology agents as well as the …
our understanding of the mechanism of action of immuno-oncology agents as well as the …
[HTML][HTML] Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk
MC Thounaojam, DF Dudimah, ST Pellom Jr… - Oncotarget, 2015 - ncbi.nlm.nih.gov
The immunosuppressive tumor microenvironment usurps host antitumor immunity by
multiple mechanisms including interference with the Notch system, which is important for …
multiple mechanisms including interference with the Notch system, which is important for …
Bortezomib improves adoptive T-cell therapy by sensitizing cancer cells to FasL cytotoxicity
A Shanker, ST Pellom Jr, DF Dudimah… - Cancer research, 2015 - AACR
Cancer immunotherapy shows great promise but many patients fail to show objective
responses, including in cancers that can respond well, such as melanoma and renal …
responses, including in cancers that can respond well, such as melanoma and renal …
[HTML][HTML] Interleukin-34 induces monocytic-like differentiation in leukemia cell lines
BE Booker, RS Clark, ST Pellom… - International journal of …, 2015 - ncbi.nlm.nih.gov
Abstract Interleukin-34 (IL-34) is a cytokine consisting of a 39kD homodimer, shown to be a
ligand for both the Macrophage Colony Stimulating Factor (M-CSF/CSF-1) receptor and the …
ligand for both the Macrophage Colony Stimulating Factor (M-CSF/CSF-1) receptor and the …
[HTML][HTML] Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009
ST Pellom, CS Rumfield, II Y Maurice Morillon… - JCI insight, 2021 - ncbi.nlm.nih.gov
There are approximately 44,000 cases of human papillomavirus–associated (HPV-
associated) cancer each year in the United States, most commonly caused by HPV types 16 …
associated) cancer each year in the United States, most commonly caused by HPV types 16 …
Butyrate regulates the expression of inflammatory and chemotactic cytokines in human acute leukemic cells during apoptosis
SR Pulliam, ST Pellom Jr, A Shanker, SE Adunyah - Cytokine, 2016 - Elsevier
Butyrate is a histone deacetylase inhibitor implicated in many studies as a potential therapy
for various forms of cancer. High concentrations of butyrate (> 1.5 mM) have been shown to …
for various forms of cancer. High concentrations of butyrate (> 1.5 mM) have been shown to …
[HTML][HTML] Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+ T cell antitumor function
ST Pellom Jr, DF Dudimah, MC Thounaojam… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Tumor-induced immune tolerance poses a major challenge for therapeutic interventions
aimed to manage cancer. We explored approaches to overcome T-cell suppression in …
aimed to manage cancer. We explored approaches to overcome T-cell suppression in …